Key facts
- It has raised $52.8M; the latest was Early Stage VC ($29.0M) in Apr 2026.
- Notable investors include Legend Capital, ZhenFund, Zhengxuan Investment, China Life Private Equity, Tiantu Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Xellar Biosystems
- ·The full record, as it builds
Funding rounds
No funding rounds for Xellar Biosystems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xellar Biosystems
Developer of a biotechnology research tool designed to accelerate drug discovery and development. The company's platform offers artificial intelligence driven modeling, machine learning integration, and wet lab experimental capabilities, enabling pharmaceutical researchers and biotechnology firms to streamline compound identification and improve therapeutic development efficiency.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Employees
- 21
- Website
- xellarbio.com/
- Ownership
- Privately Held (backing)
Xellar Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xellar Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xellar Biosystems in its N-PORT filings yet. We sweep new filings monthly.